![]() ![]() Reid Robison (MD) as Chief Clinical Officer and Dr. Numinus is also pleased to announce the appointments of Dr. "We warmly welcome the Novamind team to Numinus and believe our shared values and focus on client service will ensure a seamless integration as we continue to grow as one unified company." "This acquisition elevates our collective service offering, and we look forward to helping an even greater number of people access effective and safe treatments to support mental wellness," said Payton Nyquvest, Founder and CEO, Numinus. On a proforma basis, the combined business generated C$11.9 million of annual revenues (trailing four quarters reported, as at June 10, 2022). The transaction has also provided a strong US platform for potential continued growth in partnership and acquisition opportunities. Numinus and Novamind clients will benefit from access to a greater variety of services and treatments over the coming months, including the expansion of virtual therapy services at US-based clinics and increased group therapy offerings in Canada. This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues. As a result of the acquisition, Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies. ("Novamind") has completed, following Novamind's receipt of a final order from the BC Supreme Court. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the acquisition (the "Transaction") of Novamind Inc. VANCOUVER, BC, J/PRNewswire/ - Numinus Wellness Inc. Michael Tan has been promoted to President and Chief Operating Officer Reid Robison has been appointed Chief Clinical Officer and Paul Thielking has been appointed Chief Science Officer Novamind shareholders and RSU holders have been issued 0.84 Numinus shares per Novamind shareĪs a result of the acquisition, Novamind has ceased trading on the Canadian Securities Exchange (CSE) ![]() de la Garza’s expertise in addiction medicine and behavioral health is a vital addition to our team,” said Robison, “as we continue to expand Novamind’s clinic footprint to address unmet need and broaden our innovative, evidence-based treatments.Transaction has completed following shareholder and court approvals Novamind's Robison called de la Garza's new position in the team vital. Emerging evidence is showing the efficacy of the African root-derived medicine in treating substance addiction disorders. Bruno Rasmussen, who is a pioneer in psychedelic medicine in Latin America specializing in the use of ibogaine for substance use disorders. The Novamind-Bienstar agreement will support the expansion of Latin America's first network of integrative mental health clinics that will treat patients with psychedelic therapies.īienstar's leadership includes chief medical officer, Dr. Novamind's expansion into Salt Lake City and treatments for substance use disorder comes a few days after the company's announcement that it will enter into a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |